Articles Tagged With:
-
Full November 2004 issue in PDF
-
Clinical Briefs in Primary Care supplement
-
Pharmacology Watch: The FDA and Merck Fielding Concerns About Vioxx
Erythromycin and the Risk of Sudden Death; Vaccine Shortage Putting Americans At Risk; FDA Actions. -
Updates
Longer-Term Symptoms of WNV Fever; Hepatitis E Hits Iraq; Maggot You Another Appetizer?; SARS and the Environment. -
Persisters: Bacterial Cells That Ignore Antibiotics
Exposure of E. coli to ampicillin results in selection of a preexisting population of persister cells. Persistence may also be induced by ampicillin exposure via activation of the SOS response. -
Novel Naked Pneumococcal Naval Eye Infection: An Outbreak of Conjunctivitis
An outbreak of conjunctivitis caused by a macrolide resistant unencapsulated pneumococcus occurred among naval trainees who were receiving azithromycin as prophylaxis against atypical pneumonia. -
Empiric Therapy in the Persistently Febrile Patient With Neutropenia: Caspofungin vs Liposomal Amphotericin B
Overall, caspofungin was at least as effective as liposomal amphotericin B for empiric therapy in persistently febrile neutropenic patients. Caspofungin therapy was associated with greater survival 7 days after the end of therapy, greater efficacy in treatment of baseline fungal infections, and it was better tolerated. -
Full November 2004 issue in PDF
-
Clinical Briefs in Primary Care supplement
-
Special Feature: Chemotherapy Sensitivity/Resistance Assays in Gynecologic Cancer: Are We There Yet?
Over the last few decades, technology has existed to evaluate the cytotoxic effects of single-agent and combination chemotherapy on cancer cell lines derived from an individual patient's tumor specimens. However, investigators and clinicians have been frustrated as the fruit of this technologya reliable and reproducible assay to help them treat their patients with the agent or agents most likely to benefit themhas yet to be proven.